4 January 2016
Use of Anticholinergic Drugs Does Not Increase Risk for Dementia in Parkinson’s Disease Patients
Recent evidence has shown a greater risk of dementia, in particular Alzheimer’s disease (AD), in individuals using anticholinergic medications regularly. These drugs are widely used by older adults to treat bladder dysfunction, mood, and pain, and many of them are available without prescription. Since these drugs are often used to treat both motor symptoms and non-motor symptoms in patients with Parkinson’s Disease (PD), there is concern for increased risk of dementia. Contrary to expectations, a study in the current issue of the Journal of Parkinson’s Disease determined that the cognitive performance of PD patients taking anticholinergic medications did not differ from those who did not.
10 November 2015
Does Alcohol Consumption Affect the Risk for Parkinson’s Disease?
For many years, researchers have been investigating whether there are any associations between Parkinson’s disease (PD) and lifestyle choices such as smoking and coffee and alcohol consumption. In a review published in the Journal of Parkinson’s Disease, the literature concerning alcohol consumption presents conflicting information.
10 November 2015
Gaucher Disease May Protect Against Parkinson’s Disease-Related Color Visual Impairment
Parkinson’s Disease (PD) patients have a five-fold greater risk of carrying genetic mutations in the β-glucocerebrosidase gene (GBA), which are commonly associated with Gaucher disease (GD). Patients with both PD and GD tend to experience earlier onset of PD and more serious cognitive changes than PD patients without the mutations. A new study published in the Journal of Parkinson’s Disease suggests that GD or the presence of GBA mutations may actually shield patients from deficiency in visual color discrimination, which is a hallmark of PD.
21 October 2015
Jon Palfreman's new book: Brain Storms: The Race to Unlock the Mysteries of Parkinson’s Disease
The Journal of Parkinson’s Disease is proud to announce the publication of Media Editor Jon Palfreman’s newest book: “Brain Storms: The Race to Unlock the Mysteries of Parkinson’s Disease”, a long-overdue, riveting detective story of the race to stop or reverse neurodegenerative conditions like Parkinson's disease, and a passionate, insightful account into the lives of those affected.
Policy on Ethics
The Journal of Parkinson’s Disease affirms that misconduct, in the form of fabrication, falsification, or plagiarism, jeopardizes the success of the entire scientific endeavor. However, the primary responsibility for considering and resolving allegations of scientific misconduct must be pursued within the individual academic communities and institutions where the scientific work is carried out. Every author of articles or abstracts submitted for publication assumes full responsibility, within the limits of his or her professional competence, for the accuracy of the report. In the case of multiple-authored papers, each author should have made a significant intellectual or practical contribution to the scientific work. Authors submit articles with the understanding that reports must not have been submitted elsewhere.
Questions raised about the conduct of experiments or their presentation will be evaluated preliminarily by the Editor-in-Chief and, if appropriate, in consultation with the Associate Editor handling the review of the manuscript. If deemed appropriate, the matter will be referred to the institution where the scientific work in question was performed. The Journal expects that the matter would be reviewed in accordance with institutional procedures for handling allegations of misconduct. At all stages, every effort should be made to ensure that the process is fair and just, both for those who are accused of misconduct and for those who have raised the issue of scientific misconduct.
In the event that a published article or abstract is to be retracted, a statement of retraction will be published in the Journal of Parkinson’s Disease.
Policies
Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript. Procedures involving experiments on human subjects should be in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975. Procedures involving experimentation on animal subjects should be in accord with either the guide of the institution in which the experiments were done, or with the National Research Council’s guide for the care and use of laboratory animals.
Policy on Animal Use
The Journal of Parkinson’s Disease supports the appropriate and responsible use of animals as experimental subjects.
The U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) and the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Guide) should guide all animal research. Compliance with these guidelines as well as protocol approval by the Institutional Animal Care and Use Committee should be specified in the text of the manuscript.
We recommend following the ARRIVE reporting guidelines when documenting animal studies (PLoS Bio 8(6), e1000412, 2010).
- Office of Laboratory Animal Welfare (OLAW) PHS Policy on Humane Care and Use of Laboratory Animals, 2015 (revised March 2015). (http://grants.nih.gov/grants/olaw/olaw.htm)
- Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research.National Research Council (US) Committee on Guidelines for the Use of Animals in Neuroscience and Behavioral Research. Washington, DC; 2003. (http://www.ncbi.nlm.nih.gov/books/NBK43327/)
- Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research. PLoS Biol 8(6): e1000412. doi:10.1371/journal.pbio.1000412
Policy on Use of Human Subjects
Experiments involving human subjects must conform with the Federal Policy for the Protection of Human Subjects (United States Office of Science and Technology Policy) and in the Declaration of Helsinki and be approved by a local Institutional Review Board. Approval by the latter must be indicated in the text.
- Declaration of Helsinki. (Adopted in 1964 by the 18th World Medical Assembly in Helsinki, Finland, and revised by the 29th World Medical Assembly in Tokyo in 1975.) In: The Main Issue in Bioethics Revised Edition. Andrew C. Varga, ed. New York: Paulist Press, 1984.
- Federal Policy for the Protection of Human Subjects; Notices and Rules. Federal Register. Vol. 56. No. 117 (June 18, 1991), pp 28002-28007.
- Office for Human Research Protections (OHRP) Human Subject Protections (http://www.hhs.gov/ohrp/)
Open Access Mandates
A growing number of funding agencies now require that research articles they have funded must be made open access. This may be either by mandating deposit in repositories after an embargo period or by stipulating that research is published as open access.
Publishing in JPD complies with all major funding agency requirements.
From 2023 JPD is an Open Access Journal
From 2023 onwards JPD will be an open access journal, allowing authors the choice of two copyright licences: CC-BY-NC and CC-BY, thereby complying with all major funding mandates (you can read more about the copyright licenses here: https://creativecommons.org/about/cclicenses/). All papers published from 2023 onwards will be published in the gold open access model. All articles published as open access in JPD are automatically submitted to Pubmed Central by the publisher (there is a delay of 4-6 weeks after publication before articles are visible in Pubmed Central). The pre-2023 volume will remain as it is (part paywall, part open access)
.
Gold Open Access Publishing in JPD
Gold open access helps authors to comply with major funder mandates. Gold open access makes the article publicly available in the journal’s contents immediately upon publication. The publisher will also deposit the final, published version of the open access article into PubMed Central upon final publication. All open access articles are published under the terms of the Creative Commons Attribution Non-Commercial License 4.0.
The author will have the option to select the Creative Commons Attribution License (CC BY 4.0) copyright license for a surcharge. This license is required by certain funding agencies such as the Research Councils UK (RCUK) and Wellcome Trust.
Green Open Access Publishing in JPD for articles published pre-2023 (Self-Archiving)
Authors whose papers were published in the pre-2023 volume, who did not select open access publication, may self-archive and post the final manuscript version on their own institution, company or funding agency repositories without delay. Authors that are funded by the NIH, Research Councils UK (RCUK) and Wellcome Trust are welcome to deposit their final manuscript version to PubMed Central (Submission Method C) and Europe PubMed Central without delay. In all cases a publication reference and URL to the journal’s website must be provided on the first page of the manuscript.
Pre-Prints
JPD has no issue with authors submitting their article to a pre-print service such as BioRxiv or MedRxiv before acceptance in the journal. When submitting, do add a note clarifying that your article is available as a pre-print or in process of becoming a pre-print.
Copyright and Permissions
Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.
Quoting from other publications
An author, when quoting from someone else's work or when considering reproducing figures or table from a book or journal article, should make sure that he is not infringing a copyright. Although in general an author may quote from other published works, he should obtain permission from the holder of the copyright if he wishes to make substantial extracts or to reproduce tables, plates or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.
Permission to use content published in the Journal of Parkinson's Disease can be requested by messaging publisher@iospress.nl.
Pre-Prints
JPD has no issue with authors submitting their article to a pre-print service such as BioRxiv or MedRxiv before acceptance in the journal. When submitting, do add a note clarifying that your article is available as a pre-print or in process of becoming a pre-print.
Article Publishing Charge for Open Access
Article Publishing Charge
As of 2023 the Journal of Parkinson’s Disease is a fully open access journal. Papers submitted for publication are subject to an article publishing fee (APC). The APC for the Journal of Parkinson’s Disease is currently US$2800.
When an article is accepted for publication in the journal, the acceptance letter will give instructions regarding fulfilling the APC payment. Authors can pay the fee by credit card or through bank transfer. Payment of the APC must be received before an article is published in the journal. Paid fees are not restituted if an article is withdrawn or retracted after acceptance.
Authors may be eligible for discounts to their APC via open access agreements that Sage has with participating institutions. Discounts depend on the terms of the agreement, find out if your institution is participating by visiting the institutional agreements page at IOS Press. Eligibility is determined by the corresponding author’s affiliation at acceptance matching an agreement. Your article may be eligible for a full or partial waiver due to our participation in initiatives to increase accessibility to publication across the international academic community. . More information about discounts and eligibility.
Open Access Publishing Licenses
The Journal of Parkinson’s Disease has transitioned to a full open access journal for its 2023 volume and onwards, thereby meeting all major funders' open access publishing mandates. The standard license under which articles are published is CC BY-NC 4.0 (open access non-commercial). Authors will have the option of purchasing the CC BY 4.0 copyright license, as required by certain funding agencies, for a surcharge. For more information on these open access licenses, see https://creativecommons.org/about/cclicenses/.
More information on open access mandates (NIH/RCUK/Wellcome Trust) are available here.
Pre-Print, Proofs and Reprints
Pre-Press and Proofs
Proofs are prepared by our typesetters, Thomson Digital, and will be sent to the authors a few weeks after acceptance (typically 2-3 weeks). The corrected proofs will be placed in our online contents and indexed in PubMed as "Epub ahead of print" articles after corrections are received from the authors. The pre-press article is fully citable by using the DOI number. This is not the final version. When the article is published in an issue, the final, updated version replaces the pre-press version.
The corresponding author will receive a PDF of the proofs and is asked to check the proofs carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors. Please be sure to return your corrections as quickly as possible.
Important Note: Any changes to authors or title after acceptance should also be sent to the editorial office (jpd@iospress.com) so our records can be updated. After acceptance, any additions or deletions to the list of authors MUST be approved by the Editor-in-Chief, and all authors on the manuscript must also sign off on the changes.
Reprints and other orders
The corresponding author of a contribution to the journal receives a complimentary pdf of their published article. The pdf is automatically sent to the corresponding author after the article is published in an issue. The link to the article can be freely shared, as well as the PDF of articles published with a CC BY-4.0 license. Articles published under a CC BY-NC license cannot be shared commercially without permission, which must be granted by the publisher (permissions@iospress.com)
Print orders
Free print copies of an issue will not be provided for conference proceedings and abstract issues unless agreed upon in advance.
The possibility to place orders for reprints, additional journal copies, or print color figures can be done through an order form to which the corresponding author will be provided a link in the decision letter. If you wish to order reprints of an earlier published article, please contact the publisher for a quotation. IOS Press Email: editorial@iospress.nl.
An author is entitled to 25% discount on IOS Press books. See Author's Discount (25%) on all IOS Press book publications.
Submission Guidelines
Please note that articles submitted to the journal are required to pay an Article Publishing Charge (APC) of US$2800 on acceptance, unless a waiver has been granted. All papers will be published under an open access license. More information on this APC can be found here.
Before submitting please make sure that your article fits into the Aims and Scope: The primary focus of any submitted work should always be on Parkinson's disease or atypical parkinsonism. Research studies that focus on more heterogeneous populations, and where Parkinson's disease or parkinsonism is included merely as one of various conditions, and that do not have an explicit focus on issues related specifically to Parkinson's disease, will not be considered for publication.
SUBMISSION OF MANUSCRIPTS: AUTHOR INSTRUCTIONS
Please follow the directions of the peer review submission system. You can submit your files (document, figures, supplementary files) separately in the system, and the system will generate a final pdf for your approval. Resubmissions should include the author's replies to the reviewer comments in the revised manuscript itself (at the top) and should clearly show the changes throughout the document, for instance, by highlighting the changed text. The revised paper should always be a Word document.
Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. If your article has been published as a pre-print, it would be helpful to the Editor if you mention this in the cover letter. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript. Procedures involving experiments on human subjects should be in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975. Procedures involving experimentation on animal subjects should be in accord with either the guide of the institution in which the experiments were done, or with the National Research Council’s guide for the care and use of laboratory animals.
If the address to which proofs should be sent is different from the correspondence address, authors are kindly requested to indicate this. Both the editor and the publisher should be informed of any changes in either or both of these addresses. Please also supply a direct telephone number if available.
PREPARATION OF MANUSCRIPTS
For the author guidelines please follow the instructions given here:
About Jon Palfreman
Jon Palfreman joined the JPD editorial board as Social Media Editor in 2013. In this capacity he selected and posted news of interest to the PD research community on the JPD Facebook page. His current role relating to the JPD website is to share blog posts, that can include opinion pieces or interviews with scientists and patients, among others. He can be reached at jpalfreman @ pfgmedia.com (remove the spaces).
Biography:
Jon Palfreman, PhD is KEZI Distinguished Professor of Broadcast Journalism at the University of Oregon, USA. Palfreman is an Emmy, Dupont and Peabody Award-winning journalist, and recipient of the Victor Cohn Prize for Excellence in Medical Writing. He is a three-time winner of the American Association for the Advancement of Science science writing prize, three-time winner of the National Association of Science Writers "Science-in-Society" Journalism Award and a winner of the Writers Guild Award for best script. In the area of Parkinson's Disease research, Palfreman co-authored a book with neuroscientist Bill Langston (JPD co-Editor-in-Chief), The Case of the Frozen Addicts (Pantheon Books; 1995), and produced two NOVA documentaries chronicling the story of the MPTP cases, NOVA: The Case of the Frozen Addict, and NOVA: Brain Transplant. Palfreman is a 2006 Nieman Fellow in Journalism at Harvard University.
Book: The Case of the Frozen Addicts
In association with JPD, The Case of the Frozen Addicts: How the Solution of a Medical Mystery Revolutionized the Understanding of Parkinson's Disease, written by J. William Langston and Jon Palfreman, was published as a revised 2nd edition (IOS Press; 2014). This book describes how the solution to a baffling mystery of the brain’s chemistry opened a new frontier in medicine and restored life to people without hope. This updated edition of the classic neurological mystery tale is available in print, epub or PDF format. Read an interview with Dr Palfreman at the time of publication of the 2nd edition of Frozen Addicts here. To order your copy, see below:
*Order this book via IOS Press
Book: Brain Storms
In September 2015, Jon Palfreman’s new book “Brain Storms: The Race to Unlock the Mysteries of Parkinson's Disease” was released. Read an interview with Dr Palfreman at the time of publication of Brain Storms here. To order your copy, see below:
*Order this book in the USA
*Order this book in Canada
*Order this book in the Netherlands
Blog
The JPD blog includes news items and articles of interest to the PD research and PD patient communities. Jon Palfreman has been the primary contributor to this section since 2013 (his blog posts can be found here), joined in 2018 by Benjamin Stecher (his blog posts can be found here). In the specific sections, articles from these authors can be found and these blog posts and stories relating to PD are unique content created for the journal website. Jon Palfreman also authors two sections called Neuroscientist's Corner and The Patient Perspective. Benjamin Stecher additionally authors a section called Tomorrow Edition Extracts. Contributions from guest bloggers are also included.
Top 250 Most-Cited PD Investigators (2001–2010)
In 2011, a paper was published in JPD by Aaron Sorenson and David Weedon in which the authors listed the top 100 most-cited authors in the field of Parkinson's disease. As noted in the paper's abstract:
"The authors have compiled a list of the 100 most cited researchers in Parkinson's disease since 1985 as a means to assess productivity and impact. Within the total-citations ranking, “broad impact” citations were used as a way of identifying those researchers whose work is cited widely beyond the Parkinson's disease research community."
A longer list was compiled during that research process and here are the top 250 authors for the years 2001 to 2010 (the first 100 of which appeared in the published paper in Table 4).
View the article (2011) to read more about the analysis and selection criteria
-
Lang AE
-
Farrer MJ
-
Lees AJ
-
Olanow CW
-
Singleton A
-
Przedborski S
-
Wood NW
-
Pollak P
-
Benabid A-L
-
Poewe W
-
Jankovic J
-
Fahn S
-
Hardy J
-
Agid Y
-
Lozano AM
-
Albanese A
-
Goetz CG
-
Dawson TM
-
Cookson MR
-
Maraganore DM
-
Aarsland D
-
Brooks DJ
-
Stoessl AJ
-
Koller WC
-
Kachergus J
-
Bonifati V
-
Gasser T
-
Brice A
-
Tolosa E
-
Gwinn-Hardy K
-
Quinn NP
-
Stern MB
-
Jackson-Lewis V
-
Pahwa R
-
Mizuno Y
-
Obeso JA
-
Krack P
-
Dawson VL
-
Eidelberg D
-
Kieburtz K
-
Watts RL
-
Braak H
-
Nutt JG
-
Beal MF
-
Larsen JP
-
Rascol O
-
Wszolek ZK
-
Del Tredici K
-
Nussbaum RL
-
Vila M
-
Oertel WH
-
Hattori N
-
Klein C
-
Tanner CM
-
Bonnet A-M
-
Isacson O
-
Ondo WG
-
Volkmann J
-
Hirsch EC
-
Barker RA
-
Healy DG
-
Rüb U
-
Jenner P
-
DeLong MR
-
Deuschl G
-
Shoulson I
-
Abou-Sleiman PM
-
Dickson DW
-
Trojanowski JQ
-
Stocchi F
-
Oostra BA
-
Burn DJ
-
Youdim MBH
-
Marek K
-
de Vos RAI
-
Giladi N
-
Shults CW
-
Adler CH
-
Teismann P
-
McKeith IG
-
Berg D
-
Hauser RA
-
McNaught KStP
-
Brown P
-
Baptista MJ
-
Vitek JL
-
Meco G
-
Schapira AHV
-
Björklund A
-
Fraix V
-
Lansbury PT
-
Greenamyre JT
-
Tieu K
-
Bentivoglio AR
-
Gilks WP
-
Schwarzschild MA
-
Sampaio C
-
Vieregge P
-
Houeto J-L
-
Kulisevsky J
-
Lincoln S
-
Hulihan M
-
Johnson J
-
Oostra BA
-
Ahlskog JE
-
Heutink P
-
Vanacore N
-
Moro E
-
Rodriguez-Oroz MC
-
Rajput A
-
Hubble JP
-
Calne DB
-
Dhawan V
-
Langston JW
-
Uitti RJ
-
Valente EM
-
Siderowf A
-
Ascherio A
-
Kordower JH
-
Durr A
-
Wu DC
-
Breedveld GJ
-
Feigin A
-
Tan EK
-
Kirik D
-
Sherer TB
-
Wolters EC
-
Antonini A
-
LeWitt P
-
Hilker R
-
Lee VMY
-
Guridi J
-
Hague S
-
Sanchez-Pernaute R
-
Steur ENHJ
-
Jain S
-
Brotchie JM
-
Hernandez D
-
Weiner WJ
-
Rocca WA
-
Destee A
-
Robbins TW
-
Stacy M
-
Ravina B
-
Valldeoriola F
-
Betarbet R
-
Paisan-Ruiz C
-
Kupsch A
-
Vance JM
-
Hanson M
-
Crawley A
-
Ibanez P
-
Perlmutter JS
-
Revesz T
-
Oakes D
-
Muqit MMK
-
Brundin P
-
Riess O
-
Hunot S
-
Rudolph A
-
Emre M
-
Pezzoli G
-
Bower JH
-
Pramstaller PP
-
Wenning GK
-
West AB
-
Andersen JK
-
Rehncrona S
-
Breeze RE
-
Zimprich A
-
Dallapiccola B
-
Braak E
-
Bakay RAE
-
Freed CR
-
Choi DK
-
Biskup S
-
Suchowersky O
-
de Silva R
-
Pidoux B
-
Selkoe DJ
-
Dauer W
-
Defebvre L
-
Melamed E
-
Rizzu P
-
Greene PE
-
Pfeiffer RF
-
Reichmann H
-
Fernandez HH
-
Dillon S
-
Gironell A
-
Chabardes S
-
Kim JH
-
Scott WK
-
Levy R
-
Nicholl D
-
Sossi V
-
Chase TN
-
Lohmann E
-
Mesnage V
-
Lopiano L
-
van Duijn CM
-
Bezard E
-
Schulz JB
-
Ardouin C
-
Caputo V
-
Scerrati M
-
Kruger R
-
Bloem BR
-
Peuralinna T
-
Riederer P
-
Muller T
-
Muenter M
-
Freund HJ
-
Marder K
-
Chaudhuri KR
-
Seibyl J
-
Moore DJ
-
Van Blercom N
-
Masliah E
-
Miller D
-
Blancato J
-
Dutra A
-
Squitieri F
-
Mazzone P
-
Shinaman A
-
Iansek R
-
Krause M
-
Tronnier V
-
Bonuccelli U
-
Sturm V
-
Welter ML
-
Lichtner P
-
Weintraub D
-
Holton JL
-
Ischiropoulos H
-
Goldwurm S
-
Colcher A
-
Gandhi S
-
Latchman DS
-
de Andrade M
-
Lesnick TG
-
Samii A
-
Litvan I
-
Hernan MA
-
Kamp C
-
Bonini NM
-
Cortelli P
-
Ross OA
-
Bhatia KP
-
Guttman M
Top 250 Most-Cited PD Investigators (1985–2010)
In 2011, a paper was published in JPD by Aaron Sorenson and David Weedon in which the authors listed the top 100 most-cited authors in the field of Parkinson's disease. As noted in the paper's abstract:
"The authors have compiled a list of the 100 most cited researchers in Parkinson's disease since 1985 as a means to assess productivity and impact. Within the total-citations ranking, “broad impact” citations were used as a way of identifying those researchers whose work is cited widely beyond the Parkinson's disease research community."
A longer list was compiled during that research process and here are the top 250 authors for the years 1985 to 2010 (the first 100 of which appeared in the published paper in Table 1).
View the article (2011) to read more about the analysis and selection criteria
-
Daniel SE
-
Larsen JP
-
Hughes AJ
-
Weiner WJ
-
Müller T
-
Lazzarini AM
-
Lincoln S
-
Brown RG
-
Leroy E
-
Dutra A
-
Lavedan C
-
Dehejia A
-
Boyer R
-
DiIorio G
-
Braak H
-
Juncos JL
-
Lee VMY
-
Marder K
-
Rinne UK
-
Ahlskog JE
-
Crossman AR
-
Waters C
-
Kurlan R
-
Cookson MR
-
Kuhn W
-
Montastruc JL
-
Cote L
-
Dubois B
-
Cummings JL
-
Vieregge P
-
Riess O
-
Shannon KM
-
Snow BJ
-
Stenroos ES
-
Bergman H
-
Minoshima S
-
Kachergus J
-
Vitek JL
-
Pillon B
-
Matsumine H
-
Ide SE
-
Factor SA
-
Shimizu N
-
Asakawa S
-
Mouradian MM
-
Nagatsu T
-
Ruberg M
-
Rinne JO
-
Rocca WA
-
Burn DJ
-
Stocchi F
-
Kruger R
-
Hulihan M
-
Cooper JM
-
Isacson O
-
Melamed E
-
Papapetropoulos T
-
Athanassiadou A
-
Iansek R
-
WELLS FR
-
Durr A
-
Korczyn AD
-
Jahanshahi M
-
McKeith IG
-
Uitti RJ
-
Chandrasekharappa S
-
Pike B
-
Root H
-
Rubenstein J
-
Hurtig HI
-
Levy R
-
Owen AM
-
Damier P
-
Perry RH
-
Klein C
-
Hoffmann D
-
Hunot S
-
Stebbins GT
-
Sherer TB
-
Oakes D
-
Woitalla D
-
Rudolph A
-
Dhawan V
-
Bakay RAE
-
Giladi N
-
de Vos RAI
-
Freeman TB
-
Gibb WRG
-
Volkmann J
-
STERN GM
-
Dostrovsky JO
-
Yokochi M
-
Wenning GK
-
Kilford L
-
McDermott M
-
Perl DP
-
Welsh M
-
Betarbet R
-
Yamamura Y
-
Hornykiewicz O
-
Dickson DW
-
Brotchie JM
-
Kondo T
-
McGeer EG
-
McGeer PL
-
Del Tredici K
-
Schrag A
-
Kitada T
-
Broussolle E
-
Oostra BA
-
Deuschl G
-
Antonini A
-
Rodriguez-Oroz MC
-
Barker RA
-
Suchowersky O
-
Spillantini MG
-
Schulzer M
-
Ardouin C
-
Lynch T
-
Wichmann T
-
Parker WD
-
Schols L
-
Goedert M
-
Stern Y
-
Rub U
-
Guridi J
-
Healy DG
-
Freed CR
-
Perlmutter JS
-
Summers BA
-
Kish SJ
-
Bennett JP
-
Moro E
-
Heutink P
-
Fabbrini G
-
Abou-Sleiman PM
-
Tanaka M
-
Sahakian BJ
-
Kosel S
-
Destee A
-
Snyder SH
-
Houeto JL
-
Berg D
-
Brown P
-
Michel PP
-
Braak E
-
Kirik D
-
Gustavii B
-
Breeze RE
-
Piccini P
-
Vanacore N
-
Epplen JT
-
Johnson J
-
Ondo WG
-
Takahashi H
-
Hallett M
Submission of Manuscripts
Before submitting please make sure your article has followed the author guidelines.
Call for Papers
As of 2023 the Journal of Parkinson’s Disease is published online and in print as a fully open access journal. It offers a rigorous review process and operates with rapid manuscript processing times. The average time from submission to first decision is 18 days (the median average is 13 days).
There is an article publishing fee of US$2800 for accepted articles of the Journal of Parkinson's Disease.
Your accepted article will be freely accessible immediately upon publication, also in the Pre-Press module, as soon as payment is received. All papers will be automatically submitted to Pubmed Central by the publisher. See the publisher's website for more information on this Open Access option.
Useful Links
Subscribe
The Journal of Parkinson’s Disease (ISSN 1877-7171) is published in 1 volume of 8 issues.
Subscription Information for this journal up to 2023 can be found here at IOS Press.
From 2023 this journal will be published open access and online subscription prices will be discontinued. If you would like to subscribe to the print version of the journal from 2023 onwards, please visit the journal page at IOS Press and refer to the "print only" price.
You may also be interested in:
Journal of Alzheimer’s Disease
Journal of Huntington's Disease
Journal of Neuromuscular Diseases
Old Contact
Head Office
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0019
info@iospress.nl
For questions about submission and review of papers:
Contact information after acceptance of the paper:
For editorial matters:
editorial@iospress.nl
For publisher matters, copyright and permissions:
publisher@iospress.nl
For placing orders, claims, questions regarding existing orders, invoices etc:
order@iospress.nl
For press, marketing and promotion matters:
market@iospress.nl
For all other matters:
info@iospress.nl
Aims and Scope
The Journal of Parkinson’s Disease is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of Parkinson’s disease. The journal is international and multidisciplinary and aims to promote progress in the epidemiology, etiology, genetics, molecular correlates, pathogenesis, pharmacology, psychology, diagnosis and treatment of Parkinson’s disease. It will publish research reports, reviews, short communications, and letters-to-the-editor and offers very rapid publication and affordable open access.
Editorial Board
Editors-in-Chief
Bas Bloem, MD, PhD, FRCPE
Center of Expertise for Parkinson & Movement Disorders
Radboud University Medical Centre
Nijmegen, the Netherlands
Email: bas.bloem@iospress.com
Lorraine V. Kalia, MD, PhD, FRCPC
Division of Neurology, Department of Medicine
University of Toronto
Toronto, ON, Canada
Email: l.kalia@iospress.com
Editors-in-Chief Emeritus
Patrik Brundin, MD, PhD
Roche, Grand Rapids, MI, USA
J. William Langston, MD
Stanford University, Palo Alto, CA, USA
Associate Editor for Reviews
Rodolfo Savica
Department of Neurology, Mayo Clinic, Rochester, USA
Tiago Fleming Outeiro
Georg-August-Universität Göttingen, Göttingen, Germany
Associate Editors
Roy N. Alcalay
Columbia University, New York, USA
Roger Barker
University of Cambridge, Cambridge, United Kingdom
Erwan Bezard
University of Bordeaux, Bordeaux, France
Roongroj Bhidayasiri
Chulalongkorn University, Bangkok, Thailand
Camille B. Carroll
Newcastle University, Newcastle upon Tyne, United Kingdom
Mark R. Cookson
NIH, Bethesda, USA
Kelly D. Foote
University of Florida/Fixel Institute for Neurological Diseases, Gainesville, USA
Ziv Gan-Or
Montreal Neurological Institute, McGill University, Montreal, Canada
Glenda Halliday
The University of Sydney, Sydney, Australia
Nobutaka Hattori
Juntendo University School of Medicine, Tokyo, Japan
Jeffrey H. Kordower
Rush University, Chicago, USA
Tilo Kunath
University of Edinburgh, Edinburgh, UK
Matthew J. Lavoie
The University of Florida College of Medicine, Florida, USA
Simon J.G. Lewis
Macquarie University , Sydney, NSW, Australia
Eavan McGovern
Department of Medicine, Beaumont Hospital, Beaumont, Dublin, Ireland
Anat Mirelman
Department of Neurology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Caroline Moreau
Expert Center for Parkinson's Disease, University Hospital of Lille, Lille, France
Alice Nieuwboer
Catholic University Leuven, Leuven, Belgium
Alastair Noyce
Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom
Laurie H. Sanders
Department of Neurology, Duke University School of Medicine, Durham, NC, USA
Rick Schuurman
Amsterdam University Medical Centers, Amsterdam, the Netherlands
Antonio Strafella
Krembil Research Institute, Toronto, ON, Canada
Eng King Tan
Duke NUS Graduate Medical School, Singapore, Singapore
Aleksandar Videnovic
Massachusetts General Hospital, Harvard Medical School, Boston, USA
Mayela Rodriguez Violante
Clinical Laboratory of Neurodegenerative Diseases, INNNMVS, Mexico City, Mexico
Nienke M. de Vries
University Medical Center Groningen , University of Groningen, Groningen, the Netherlands
Doris Wang
Neurological Surgery, School of Medicine, University of California, San Francisco, USA
Jian Wang
Huashan Hospital, Fudan University, Shanghai, China
Amanda L. Woerman
Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA
Suneil Kalia, MD, PhD
Department of Surgery, University of Toronto, Toronto, ON, Canada
Associate Editors of Clinical Trials Highlights
Kevin McFarthing
Parkinson’s Advocate, Innovation Fixer Ltd, Oxford, UK
Tanya Simuni
Parkinson's Disease and Movement Disorders Center,
Northwestern University Feinberg School of Medicine, Chicago, USA
Associate Editor of Hidden Gems
Peter A. LeWitt
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
Associate Editor for Statistics
Jeremy Syrjanen
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, USA
Social Media Editor
Carolina L. Soares
Department of Neurology, ULS São João, Porto, Portugal; Department of Medicine, Faculty of Medicine of University of Porto, Porto, Portugal
Managing Editor
Beth Kumar
Case Western Reserve University, Cleveland, USA
Email: jpd@iospress.com
Editorial Board
Dag Aarsland
University of Stavanger, Stavanger, Norway
Asa Abeliovich
Columbia University College of Physicians & Surgeons, New York, USA
Yves Agid
Institut du Cerveau et de la Moelle épinière, Paris, France
Alberto Albanese
National Neurological Hospital Carlo Besta, Milan, Italy
Ernest Arenas
Karolinska Institute, Stockholm, Sweden
Alberto Ascherio
Harvard School of Public Health, Boston, USA
Alim Benabid
University of Grenoble, Grenoble, France
Daniela Berg
Christian-Albrechts-Universität zu Kiel, Kiel, Germany
Hagai Bergman
The Hebrew University, Jerusalem, Israel
Erwan Bezard
University of Bordeaux, Bordeaux, France
Anders Björklund
Lund University, Lund, Sweden
David J Blacker
Perron Institute for neurological and translational science, Nedlands, Australia
Vincenzo Bonifati
Erasmus MC, Rotterdam, the Netherlands
Heiko Braak
University of Ulm, Ulm, Germany
Jose Bras
University College London, London, UK
Alexis Brice
Pierre and Marie Curie University, Paris, France
Helen Bronte-Stewart
Stanford University, Palo Alto, USA
David J. Brooks
Hammersmith Hospital, London, United Kingdom
Paolo Calabresi
Policlinico Gemelli, Catholic University, Rome, Italy
M. Angela Cenci Nilsson
Lund University, Lund, Sweden
Piu Chan
Beijing Institute of Geriatrics, Beijing, China
K. Ray Chaudhuri
Kings College Hospital, London, United Kingdom
Marie Francoise Chesselet
University of California Los Angeles, Los Angeles, USA
Cynthia Comella
Rush University Medical Center, Chicago, USA
Ted M. Dawson
Johns Hopkins University School of Medicine, Baltimore, USA
Valina L. Dawson
Johns Hopkins University School of Medicine, Baltimore, USA
Benjamin Dehay
University of Bordeaux, Bordeaux, France
Steve DeWitte
Connecticut Advocates for Parkinson's, New Preston Marble Dale, USA
Dennis Dickson
Mayo Clinic, Scottsdale, USA
Robert H. Edwards
University of California San Francisco, San Francisco, USA
David Eidelberg
The Feinstein Institute for Medical Research, New York, USA
Omar M. El-Agnaf
United Arab Emirates University, Al-Ain, United Arab Emirates
Alberto Espay
University of Cincinatti, Cincinatti, USA
Stanley Fahn
Columbia University College of Physicians & Surgeons, New York, USA
Matt Farrer
University of British Columbia, Vancouver, Canada
Howard Federoff
Georgetown University, Washington, USA
Joaquim Ferreira
Hospital de Santa Maria, Lisbon, Portugal
Tom Foltynie
University College London, London, UK
Thomas Gasser
University of Tuebingen, Tuebingen, Germany
Larry Gifford
PD Avengers, Vancouver, BC, Canada
Nir Giladi
Tel Aviv University, Tel Aviv, Israel
Ann M. Graybiel
MIT, Cambridge, USA
J. Timothy Greenamyre
University of Pittsburgh, Pittsburgh, USA
James G. Greene
Emory University, Atlanta, USA
Rita Guerreiro
University College London, London, UK
Mark Hallett
NIH, Bethesda, USA
Hannington Kabugo
Parkinson's si Buko Uganda, Kampala, Uganda
John Hardy
University College London, London, United Kingdom
Etienne C. Hirsch
Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière, Paris, France
Joseph Jankovic
Baylor College of Medicine, Houston, USA
Christine Klein
University of Lübeck, Lübeck, Germany
Han Seok Ko
Johns Hopkins, Baltimore, USA
Amos D. Korczyn
Tel Aviv University, Ramat Aviv, Israel
Dimitri Krainc
Northwestern University, Chicago, USA
Emma L. Lane
Cardiff University, Cardiff, Wales, UK
Seung-Jae Lee
Konkuk University, Seoul, South Korea
Virginia Lee
University of Pennsylvania School of Medicine, Philadelphia, USA
Peter A. LeWitt
Wayne State University, Detroit, USA
Henry Ford Hospital, Detroit, USA
Olle Lindvall
Lund University, Lund, Sweden
Andres Lozano
University of Toronto, Toronto, Canada
Laura Marsh
Baylor College of Medicine, Houston, USA
Ian Martin
Oregon Health & Science University, Portland, USA
Soania Mathur
Designing a Cure Inc., Toronto, Canada
Mark P. Mattson
Johns Hopkins University School of Medicine, Baltimore, USA
Wassilios Meissner
University Hospital Bordeaux, Bordeaux, France
Darren Moore
Van Andel Institute, Grand Rapids, USA
Robert Nussbaum
University of California San Francisco, San Francisco, USA
Tiago Outeiro
University Medical Center Göttingen, Göttingen, Germany
Jon Palfreman
University of Oregon, Eugene, USA
Ronald F. Pfeiffer
Oregon Health and Sciences University, Portland, USA
Serge Przedborski
Columbia University Medical Center, New York, USA
Heinz Reichmann
University of Dresden, Dresden, Germany
Tamas Revesz
University College London, London, United Kingdom
Olaf Riess
University of Tuebingen, Tuebingen, Germany
Trevor Robbins
University of Cambridge, Cambridge, United Kingdom
Marina Romero Ramos
Aarhus University, Aarhus, Denmark
Anthony Schapira
University College London, London, United Kingdom
Sonja Scholz
NIH, Bethesda, USA
Jie Shen
Harvard Medical School, Boston, USA
Todd Sherer
Michael J. Fox Foundation, New York, USA
Ira Shoulson
Georgetown University, Washington, USA
Andrew Singleton
NIH, Bethesda, USA
Richard Smeyne
Thomas Jefferson University, Philadelphia, USA
Yoland Smith
Emory University, Atlanta, USA
Jon Stamford
Parkinson's Movement & The Cure Parkinson's Trust, London, United Kingdom
David G. Standaert
University of Alabama at Birmingham, Birmingham, USA
Leonidas Stefanis
University of Athens Medical School, Athens, Greece
Dennis Steindler
University of Florida, Gainesville, USA
Benjamin Stecher
tmrwedition.com, Toronto, Canada
Fabrizio Stocchi
IRCCS San Raffaele, Rome, Italy
A. Jon Stoessl
University of British Columbia, Vancouver, Canada
David L Sulzer
Columbia University, New York, USA
James Dalton Surmeier
Northwestern University, Chicago, USA
Michele Tagliati
Cedars-Sinai Medical Center, Los Angeles, USA
Jun Takahashi
Kyoto University, Kyoto, Japan
Caroline M. Tanner
The Parkinson's Institute and Clinical Center, Sunnyvale, USA
Malú G Tansey
University of Florida College of Medicine, Gainesville, USA
Bobby Thomas
Medical University of South Carolina, Charleston, USA
Eduardo Tolosa
University of Barcelona, Barcelona, Spain
Jens Volkmann
Universitätsklinikum Wurzburg, Wurzburg, Germany
Laura Volpicelli-Daley
The University of Alabama at Birmingham, Birmingham, USA
Daniel Weintraub
University of Pennsylvania, Philadelphia, USA
Nick Wood
University College London, London, United Kingdom
Zhenyu Yue
Icahn School of Medicine at Mount Sinai, New York, USA
Founding Editors from the Journal of Alzheimer’s Disease
George Perry
University of Texas at San Antonio, San Antonio, USA
Mark A. Smith†
Case Western Reserve University, Cleveland, USA
Advertising
Please contact market@iospress.nl for your advertising proposals and requests.
About the Journal
The Journal of Parkinson's Disease (JPD) publishes original research in basic science, translational research and clinical medicine in Parkinson’s disease in cooperation with the Journal of Alzheimer's Disease. It features a first class Editorial Board and provides rigorous peer review and rapid online publication.
Publication
From 2022, the journal publishes eight issues per annual volume; prior to this it was four issues per year. From 2023 the journal will proceed as an open access publication, where all articles from the 2023 volume onwards will be openly available.
Impact Factor
JPD has a Journal Impact Factor of 5.2, and a CiteScore of 6.9 (2023 Journal Citation Reports, source: Clarivate, 2023).
Abstracted/Indexed in
Chemical Abstracts Service (CAS), Embase, Journal Citation Reports/Science Edition, MEDLINE, PsycINFO, PubsHub, Science Citation Index-Expanded (SciSearch®), Scopus
News & Social Media
View a selection of newsletters that were sent out recently by clicking on the links:
2020: Issue 1; Issue 2; Issue 3; Issue 4; Special Issue; Parkinson Prize 2020
To receive news and JAD updates, sign up via this link: http://tiny.cc/JPDsignup
Find JPD on Facebook at: facebook.com/journalpd
Follow JPD on Twitter at: twitter.com/journal_pd
The Publisher
IOS Press publishes publishes around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in biomedical and life sciences (including neurosciences, medical informatics, cancer research, rehabilitation) and physical sciences (including computer sciences, artificial intelligence, engineering).
Headquartered in Amsterdam with satellite offices in the USA, Germany and China, IOS Press continues its rapid growth, embracing new technologies for the timely dissemination of information.
All journals are available in print and electronic format.
24 June 2015
New Study Calls for Partnering of Parkinson’s Disease Research Community with Patient Groups to Improve Effectiveness of Clinical Trials
Despite an urgent need for new medications, clinical trials in Parkinson’s disease (PD) have a relatively low rate of success. The reasons for this are complex, prompting a group of investigators from PD advocacy groups to conduct a survey of the principle stakeholders, PD scientists, patients, and caregivers, to determine some of the underlying barriers. Their results are published in the Journal of Parkinson’s Disease.
24 June 2015
What Is the Role of the Gut Microbiome in Developing Parkinson’s Disease?
In recent years, an important Parkinson’s disease (PD) research focus has been on gut-related pathology, pathophysiology, and symptoms. Gastrointestinal dysfunction, in particular constipation, affects up to 80% of PD patients and idiopathic constipation is one of the strongest risk-factors for PD. Lifestyle factors such as smoking and coffee consumption, as well as blood urate levels, have been associated with a decreased PD risk.
26 February 2015
Levodopa-Carbidopa Intestinal Gel May Prove More Effective for Long-Term Treatment of Parkinson’s Disease than Standard Levodopa
Although levodopa remains the “gold standard” to effectively control motor deficits in the treatment of early stage Parkinson’s disease (PD), it loses effectiveness as the disease progresses. After four to six years of treatment with oral medications for Parkinson’s disease, about 40% of patients experience lack of muscle control (dyskinesias), end-of-dose wearing off, and fluctuations in “On/Off” states. By nine years of treatment, about 90% will suffer these effects.
25 February 2015
Parkinson’s Disease Patients Have Reduced Visual Contrast Acuity
Patients with Parkinson’s disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson’s Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients’ vision was deficient at far distances.
18 November 2014
Simple Clinical Tests Help Differentiate Parkinson’s Disease from Atypical Parkinsonism
Two simple tests conducted during the neurological exam can help clinicians differentiate between early-stage Parkinson’s disease (PD) and atypical parkinsonism. By asking patients to perform a tandem gait test and inquiring whether they are still able to ride a bicycle, clinicians can ascertain whether medio-lateral balance is impaired, a defining characteristic of atypical parkinsonism. These findings are published in the Journal of Parkinson’s Disease.
11 September 2014
Few Mild-to-Moderate PD Patients Suffer from Malnutrition, Yet Almost One Third Are at Risk
Patients with Parkinson’s disease (PD) can experience difficulties with food preparation and ingestion, which could contribute to poor nutrition and place them at risk for malnourishment. Published studies have also suggested that PD is associated with low weight, however, few studies included control groups. A report published in the Journal of Parkinson’s Disease counters this conclusion in patients with mild-to-moderate PD, finding that the incidence or risk of malnutrition is no different for patients with mild-to-moderate PD compared to healthy controls.
9 July 2014
Sleep Disturbances, Common in Parkinson’s Disease, Can Be Early Indicator of Disease Onset
Up to 70% of Parkinson’s disease (PD) patients experience sleep problems that negatively impact their quality of life. Some patients have disturbed sleep/wake patterns such as difficulty falling asleep or staying asleep, while other patients may be subject to sudden and involuntary daytime sleep “attacks.” In the extreme, PD patients may exhibit REM-sleep behavior disorder (RBD), characterized by vivid, violent dreams or dream re-enactment, even before motor symptoms appear. A review in the Journal of Parkinson’s Disease discusses the underlying causes of sleep problems in PD, as well as medications, disease pathology, and comorbidities, and describes the most appropriate diagnostic tools and treatment options.
24 June 2014
Deep Brain Stimulation Improves Non Motor Symptoms in Parkinson’s Disease as well as Motor Symptoms
Deep brain stimulation (DBS) has become a well-recognized non- pharmacologic treatment that improves motor symptoms of patients with early and advanced Parkinson’s disease. Evidence now indicates that DBS can decrease the number and severity of non motor symptoms of patients with Parkinson’s disease (PD) as well, according to a review published in the Journal of Parkinson’s Disease.
13 May 2014
Exenatide Has Potential as a Disease Modifying Agent in Parkinson’s Disease
A follow-up study of patients with Parkinson’s disease (PD) who participated in an earlier “proof of concept” clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers in the Journal of Parkinson’s Disease.
17 January 2014
Higher Vitamin D Levels Associated with Better Cognition and Mood in Parkinson’s Disease Patients
A new study exploring vitamin D levels in patients with Parkinson’s disease (PD) opens up the possibility of a new avenue of early intervention that may delay or prevent the onset of cognitive impairment and depression. The findings are published in the Journal of Parkinson’s Disease.
Pages
